Lung effects during a generalized Shwartzman reaction and therapeutic intervention with dexamethasone or vitamin E.
We investigated if a two-hit shock model, commonly referred to as generalized Shwartzman reaction (GSR), can prime for indirect acute respiratory distress syndrome (ARDS) in mice. The GSR was provoked in C57BL/6 mice by two consecutive i.p. injections of 100 microg lipopolysaccharide (LPS) at t = 0 and t = 20 h. These mice demonstrated a dramatic decrease in respiratory capacity and 80% mortality after the second injection. No such effect was observed when LPS was given as a single 200 microg dose at t = 0. Increased expression of proinflammatory cytokines in serum (interleukin-1beta, interleukin-6 and interferon-gamma), lung neutrophilia, and edema formation were observed in mice injected with one dose of LPS, but notably, mice exposed twice did not further increase their inflammatory response. Early treatment 1 h after the first LPS injection (t = 1 h) with either dexamethasone (10 mg/kg) or vitamin E (50 mg/kg) improved respiratory function and down-modulated the induction of proinflammatory cytokines in serum. In conclusion, mice with a generalized Shwartzman reaction exhibited features resembling some aspects of the pathophysiology in septic ARDS, i.e., neutrophilic inflammation, edema formation, impaired respiratory capacity, and mortality. Our data indicate that a systemic cytokine response and lung neutrophilia may prime for the GSR but that other mechanisms account for the rapid decline in lung function after the second challenge. We suggest that this model can be used for studies of pathogenesis and therapeutic prevention of acute respiratory failure.
Rocksén
David
D
Department of Medical Countermeasures, Divison of NBC Defence, Swedish Defence Research Agency, Umeå, Sweden. david.rocksen@foi.se
Koch
Bo
B
Sandström
Thomas
T
Bucht
Anders
A
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology*; D015536:Down-Regulation; D004487:Edema; D004797:Enzyme-Linked Immunosorbent Assay; D005938:Glucocorticoids / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000737:chemistry; D008168:Lung / Q000187:drug effects* / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008856:Microscopy, Fluorescence; D009504:Neutrophils / Q000378:metabolism; D010101:Oxygen Consumption; D018805:Sepsis; D012790:Shwartzman Phenomenon / Q000188:drug therapy*; D013997:Time Factors; D014810:Vitamin E / Q000494:pharmacology*
D000975:Antioxidants; D016207:Cytokines; D005938:Glucocorticoids; D008070:Lipopolysaccharides; D014810:Vitamin E; D003907:Dexamethasone